Who
Terrance P. Coyne
EVP & CFO
Company insider
Files Form 4 as: EVP & CFO, Royalty Pharma.
In numbers
- Trades disclosed
- 106
- Buys
- 1
- Sells
- 25
- Bought
- $83K
- Sold
- $83.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 15 Jun 2020
- Last trade
- 13 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 17 Aug 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $541K9,230 at $58.59 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $105K1,772 at $59.14 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $541K9,230 at $58.59 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $105K1,772 at $59.14 | filing |
| 7 Aug 2026filed 7 Aug 2026 | RPRX Royalty Pharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code G | —18,500 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | RPRX Royalty Pharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code G | —18,500 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —11,002 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —11,002 at $0.00 | filing |
| 26 May 2026filed 28 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $3.5M64,399 at $53.98 | filing |
| 26 May 2026filed 28 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $3.5M64,399 at $53.98 | filing |
| 6 May 2026filed 8 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —24,263 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —24,263 at $0.00 | filing |
| 28 Apr 2026filed 30 Apr 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $1.6M32,916 at $49.78 | filing |
| 28 Apr 2026filed 30 Apr 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $93K1,875 at $49.78 | filing |
| 28 Apr 2026filed 30 Apr 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $1.6M32,916 at $49.78 | filing |
| 28 Apr 2026filed 30 Apr 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $93K1,875 at $49.78 | filing |
| 1 Apr 2026filed 2 Apr 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $91K1,875 at $48.33 | filing |
| 1 Apr 2026filed 2 Apr 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $1.6M32,916 at $48.33 | filing |
| 1 Apr 2026filed 2 Apr 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $91K1,875 at $48.33 | filing |
| 1 Apr 2026filed 2 Apr 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $1.6M32,916 at $48.33 | filing |
News
Head to Head Review: Royalty Pharma (NASDAQ:RPRX) versus Biofrontera (NASDAQ:BFRI)RPRX · themarketsdaily.com · 25 Oct 2026Analyzing Royalty Pharma (NASDAQ:RPRX) and Chugai Pharmaceutical (OTCMKTS:CHGCY)RPRX · themarketsdaily.com · 23 Oct 2026Head to Head Contrast: Royalty Pharma (NASDAQ:RPRX) versus Nexentis Technologies (NASDAQ:NXTS)RPRX · dailypolitical.com · 22 Oct 2026
0 headlines in the last 90 days name Terrance P. Coyne; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.